Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oso Biopharmaceuticals Manufacturing has completed the purchase of Catalent Pharma Solutions's Albuquerque, New Mexico sterile injectables manufacturing business.
Subscribe to our email newsletter
The Albuquerque business provides cGMP glass vial filling and lyophilization services for injectable drugs and biologics that are either approved for commercial marketing or in clinical development. Oso Biopharmaceuticals will retain all employees associated with the business and continue to serve all existing customers in North America and Europe.
Altaris Capital Partners, a healthcare investment firm, collaborated with Oso Biopharmaceuticals and provided capital for the transaction.
Stuart Rose, CEO and president of Oso Biopharmaceuticals, said: “We are delighted to have been successful in acquiring Catalent’s sterile injectables business based in Albuquerque. It fits exceedingly well with our strategy to build a world class, high quality contract manufacturing company. We will work tirelessly with the talent pool in Albuquerque to meet the highest demands and expectations of our global customer base.”